帕博利珠单抗治疗浸润性膀胱尿路上皮癌患者后出现未分化尿路上皮癌：一例报告
Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report.
作者信息
Hasegawa Moto, Hasegawa Go, Ikeda Yohei, Hara Noboru, Nishiyama Tsutomu
机构信息
Department of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan.
Department of Pathology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan.
出版信息
SAGE Open Med Case Rep. 2020 Jun 13;8:2050313X20932694. doi: 10.1177/2050313X20932694. eCollection 2020.
An 83-year-old man received pembrolizumab treatment after anticancer chemotherapy with gemcitabine and cisplatin for advanced bladder cancer. Pathological findings revealed invasive urothelial carcinoma with squamous differentiation before treatment. After seven courses of pembrolizumab treatment, the tumor disappeared. After 15 courses of the treatment, the tumor regrew. Pathological findings revealed invasive undifferentiated urothelial carcinoma consisting of relatively small tumor cells of the same size as lymphocytes, negative for neuroendocrine markers. Programmed death-ligand 1 expressions in tumor tissue changed from positive before treatment to negative after pembrolizumab treatment.
一名83岁男性在接受吉西他滨和顺铂的抗癌化疗后，因晚期膀胱癌接受了帕博利珠单抗治疗。病理检查结果显示，治疗前为伴有鳞状分化的浸润性尿路上皮癌。经过七个疗程的帕博利珠单抗治疗后，肿瘤消失。在接受15个疗程的治疗后，肿瘤复发。病理检查结果显示为浸润性未分化尿路上皮癌，由与淋巴细胞大小相同的相对较小的肿瘤细胞组成，神经内分泌标志物呈阴性。肿瘤组织中程序性死亡配体1的表达从治疗前的阳性变为帕博利珠单抗治疗后的阴性。
Zotero 插件